AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$65.65
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | ABBV Avg Daily Volume: 7,086,700
Last Update: 03/23/17 - 4:01 PM EDT
Volume: 0
YTD Performance: 4.84%
Open: $0.00
Previous Close: $65.65
52 Week Range: $55.06 - $68.12
Oustanding Shares: 1,593,576,738
Market Cap: 104,411,147,874
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 5
Moderate Buy 1 1 1 1
Hold 8 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.50 2.50 2.50 2.40
Latest Dividend: 0.64
Latest Dividend Yield: 3.91%
Dividend Ex-Date: 04/11/17
Price Earnings Ratio: 13.59
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
13.59 18.00 30.30
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.31% 16.48% 22.80%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.40 0.11
Net Income 15.70 0.40 0.13
EPS 15.50 0.40 0.12
Earnings for ABBV:
EBITDA 9.38B
Revenue 25.64B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.26 $1.39 $5.49 $6.52
Number of Analysts 7 6 11 10
High Estimate $1.31 $1.44 $5.53 $7.06
Low Estimate $1.23 $1.36 $5.46 $6.24
Prior Year $1.15 $1.26 $4.82 $5.49
Growth Rate (Year over Year) 9.44% 10.58% 13.99% 18.57%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

bullishAbbvie added to Conviction Buy List at Goldman

Mar 10, 2017 | 6:51 AM EST
ABBV was placed on the Conviction Buy list, according to Goldman Sachs. $80 price target. Company is growing faster than its peers, but trades at a discount.
RMPIA
By

Jim Cramer

 | Feb 22, 2017 | 11:45 AM EST
Icahn may have a tough time finding interest in this behemoth.
RMPIA
By

Bruce Kamich

 | Feb 16, 2017 | 11:18 AM EST
You might want to review your holdings in the sector.
RMPIA
By

Mark Sebastian

 | Feb 7, 2017 | 5:22 PM EST
Would get drugs to market faster and possibly more cheaply.
RMPIA
By

Mark Sebastian

 | Feb 7, 2017 | 2:48 PM EST
Getting FDA to streamline its approval process would boost drug makers.
RMPIA
By

Bret Jensen

 | Feb 1, 2017 | 11:30 AM EST
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
RMPIA
By

David Katz

 | Jan 27, 2017 | 8:00 AM EST
Value stocks will extend their outperformance over growth stocks that began last year.
RMPIA
By

Bret Jensen

 | Jan 17, 2017 | 11:00 AM EST
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
RMPIA
By

Bret Jensen

 | Jan 12, 2017 | 11:00 AM EST
But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
RMPIA
By

Bret Jensen

 | Dec 16, 2016 | 8:58 AM EST
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this segment of the market in 2016 and I still believe there is value here.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.